Truist Financial
UNCY icon

Truist Financial’s Unicycive Therapeutics UNCY Stock Holding History

Truist Financial’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,746
Closed -$48K – 2780
2022
Q1 		$48K Buy
+3,746
New +$54.9K ﹤0.01% 2636

Other funds holding UNCY

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
TCM
Tandem Capital Management Woodcliff Lake, New Jersey $200M AUM 25.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Truist Financial's UNCY Position: Q2 2022 in Review

Truist Financial sold out of Unicycive Therapeutics (UNCY) in Q2 2022, closing a stake of 3,746 shares — an estimated $48K sold.

Truist Financial first reported a position in UNCY in Q1 2022 and held it in 1 quarter. The position peaked at $48K in Q1 2022. 15 funds tracked by Wall St. Rank hold UNCY as of Q2 2022.

  • Truist Financial reported no remaining Unicycive Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Truist Financial sold 3,746 Unicycive Therapeutics shares in Q2 2022, an estimated $48K.
  • Truist Financial first reported a position in Unicycive Therapeutics in Q1 2022 and held it in 1 quarter.
  • Truist Financial's Unicycive Therapeutics position peaked at $48K in Q1 2022.
  • 15 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2022.

Based on Truist Financial's 13F filing for Q2 2022, filed 22 Jul 2022.